• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Neuro-Oncology >OS07.7 Patterns of diagnostic marker assessment in adult diffuse glioma - a survey of the European Confederation of Neuropathological Societies
【2h】

OS07.7 Patterns of diagnostic marker assessment in adult diffuse glioma - a survey of the European Confederation of Neuropathological Societies

机译：OS07.7成人弥漫性神经胶质瘤诊断标志物评估模式-欧洲神经病理学会联合会的一项调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Introduction: The 2016 update of the WHO classification has introduced an integrated diagnostic approach that incorporates both tumor morphology and molecular information. This conceptual change has far reaching implications especially for neuropathologists who are in the forefront of translating molecular markers to routine diagnostic use. Adult diffuse glioma is a prototypic example for a group of tumors that underwent substantial regrouping, and it represents a major workload for surgical neuropathologists. METHODS: We conducted a survey among members of the European Confederation of Neuropathological Societies (Euro-CNS) in order to assess 1) the extent to which molecular markers have already been incorporated in glioma diagnoses, 2) which molecular techniques are in daily use, and 3) to set a baseline for future surveys in this field. >Results: Based on 130 responses from participants across 40 nations neuropathologists uniformly rate molecular marker testing as highly relevant and already incorporate molecular information in their diagnostic assessments. At the same time however, the survey documents substantial differences in access to crucial biomarkers and molecular techniques across geographic regions and within individual countries. Concerns are raised concerning the validity of test assays with MGMT, 1p19q, and ATRX being perceived as most problematic. >Conclusions: Together neuropathologists advocate the need for international harmonization of standards and consensus guidelines, and the majority is willing to actively engage in quality control.
机译：>简介：2016年WHO分类更新更新引入了一种综合诊断方法，该方法结合了肿瘤形态学和分子信息。这种观念上的改变具有深远的意义，特别是对于那些将分子标记物转化为常规诊断用途最前沿的神经病理学家而言。成人弥漫性神经胶质瘤是一组经过实质性重组的肿瘤的原型实例，它代表了外科神经病理学家的主要工作量。方法：我们对欧洲神经病理学会联合会（Euro-CNS）成员进行了一项调查，以评估1）胶质瘤诊断中已经整合了分子标记的程度，2）日常使用的分子技术，和3）为该领域的未来调查设定基线。 >结果：基于来自40个国家/地区的参与者的130份反馈，神经病理学家一致认为分子标记物测试具有高度相关性，并且已经将分子信息纳入其诊断评估中。然而，与此同时，该调查记录了跨地理区域和单个国家获得关键生物标志物和分子技术的巨大差异。有人担心MGMT，1p19q和ATRX被认为是最有问题的测试方法的有效性。 >结论：神经病理学家一道主张对国际标准和共识准则进行统一的需求，并且大多数人都愿意积极参与质量控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号